Plain-English translation of NCT00801489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment made up of five chemotherapy drugs — fludarabine, , filgrastim, , and — in patients with newly diagnosed acute myeloid leukemia (AML) that has specific genetic changes. The goal is to see whether this medication combination is safe and how well it helps patients achieve remission (when leukemia cells disappear). Researchers will also track how long patients stay in remission after treatment.
Acute myeloid leukemia is a serious blood cancer, but certain genetic patterns within the cancer cells respond better to treatment. This trial is designed to see if combining these five medications in a specific way can improve remission rates and survival for patients with these particular genetic subtypes.
You likely qualify if…
You likely don't qualify if…
You will first receive an induction phase where you get the medication combination intravenously over several days to try to put your leukemia into remission. If remission is achieved, you will then enter a post-remission phase with up to 6 courses of treatment given every 4 to 6 weeks, with the medication doses and schedule adjusted based on your response and age. Throughout treatment, you will have regular blood tests and monitoring visits to track how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States